Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01337752 | Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency | PHASE2 | COMPLETED | 9 | — | — | Jan 1, 2012 | May 1, 2013 | Dec 17, 2020 | 8 | United States, Spain +1 |
Time to first SRE from randomization
| Arm | Type | Description |
|---|---|---|
| BHQ880 + bortezomib and dexamethasone | EXPERIMENTAL | - |
| BHQ880 Placebo + bortezomib and dexamethasone | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BHQ880 | DRUG | - |
| BHQ880 Placebo | DRUG | Intravenous infusion |
| bortezomib | DRUG | intravenous injection |
| dexamethasone | DRUG | Oral |
Inclusion Criteria: 1. Confirmed diagnosis of multiple myeloma 2. Life expectancy of more than 6 months in the absence of intervention 3. Must not have received previous or be receiving current antimyeloma therapies 4. Renal insufficiency 5. Recovered from the effects of any prior surgery or radiot...